Greater Cannabis CO Inc (OP: GCAN )

0.0007 -0.0001 (-12.50%)

Streaming Delayed Price Updated: 10:27 AM EDT, Jul 9, 2024 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	177,667
Open	0.0007
Bid (Size)	N/A (0)
Ask (Size)	N/A (0)
Prev. Close	0.0008
Today's Range	0.0007 - 0.0007
52wk Range	0.0004 - 0.0015
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Can Marijuana Treat Autism, OCD & Irritable Bowel Syndrome? Ohio Medical Panel Will Investigate

February 13, 2023

Ohio researchers want to learn more about the effects of medical marijuana on those with autism spectrum disorder (ASD), obsessive-compulsive disorder (OCD) and irritable bowel syndrome, reported...

Via Benzinga

Cannabinoids & Autism Spectrum Disorder: This Baltimore Company Is On Track To Start Phase 2 Clinical Trial For New Treatment

October 07, 2022

Cannabinoid-focused biopharmaceutical company Greater Cannabis Company, Inc. (OTC: GCAN) has submitted a clinical trial application to the Israel Ministry of Health for approval of Phase 2 clinical...

Via Benzinga

Performance

YTD	-12.50%	-12.50%
1 Month	N/A	N/A
3 Month	N/A	N/A
6 Month	-12.50%	-12.50%
1 Year	-12.50%	-12.50%

More News

GCANRx Announces Submission of Phase 2 Clinical Trial Application to Treat Autism Related Spectrum Disorders

October 07, 2022

From The Greater Cannabis Company, Inc.

Via GlobeNewswire

Cannabis Movers & Shakers: Coda Signature, Greater Cannabis Co., BioHarvest Sciences, Compass Pathways

December 06, 2021

Via Benzinga

Greater Cannabis Partners with Shaare Zedek Scientific on Innovative Neuropsychiatric Cannabinoid Therapy

August 30, 2021

Via Benzinga

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.